Philips Launches IntraSight Interventional Applications Platform

May 20, 2019 — Philips announced the launch of the new IntraSight interventional applications platform. The secure, application-based platform offers a comprehensive suite of clinically proven instant wave-free ratio (iFR), fractional flow reserve (FFR), intravascular ultrasound (IVUS) and co-registration1 modalities to simplify complex interventions and speed routine procedures.

In image-guided treatments of the heart and peripheral blood vessels, there is an increasing trend to use advanced catheters and pressure wires that are capable of producing ultrasound images of the interior of blood vessels (IVUS) and perform blood pressure measurements (FFR and iFR). There is a growing body of clinical evidence that the use of such technologies in conjunction with interventional X-ray improves patient outcomes.

“IntraSight has made an immediate impact in our lab,” said Rasha Al-Lamee, M.D., clinical academic interventional cardiology consultant at Imperial College Healthcare NHS Trust, London, U.K. “It is so simple and intuitive to use that it took us no time at all to get used to it. It has made using physiology and imaging even quicker and easier, which is a great advance for us and for our patients.”

Philips IntraSight optimizes lab performance with tableside touchscreen control, systems integration, data management and remote service diagnostics. The combination of IntraSight and Azurion, Philips’ image-guided therapy platform, provides a level of diagnostic insight and intuitive tableside control that enables clinicians to provide cardiac and peripheral vascular patients with superior care. IntraSight delivers an outstanding user experience, according to Philips. with a modern, intuitive interface that minimizes learning curves and increases workflow confidence.

Further providing seamless integration in the interventional lab, Philips SyncVision, available on IntraSight 4, advances patient care by mapping both the pressure profile and IVUS measurements of the whole vessel onto the angiogram. With iFR pullback and co-registration and IVUS co-registration1, physicians can identify the precise locations causing ischemia, plan stent length and placement with a virtual stent, and predict physiologic improvement.

iFR is a pressure-derived index proprietary to Philips, allowing a simplified hyperemia-free physiological assessment of coronary blockages. It continues to be adopted into clinical practice, with mounting evidence the technology contributes to reducing costs, improving outcomes 2, 3, 4 and enhancing the patient experience.

IntraSight will be showcased at the Society for Cardiovascular Angiography and Interventions (SCAI)scientific sessions, May 19-22 in Las Vegas, and EuroPCR, May 21-24 in Paris, France.

For more information: www.usa.philips.com/healthcare

References

1. Co-registration tools available within IntraSight 7 configuration via SyncVision.

2. Davies J.E., et al. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017 May 11;376(19):1824-1834.

3. Gotberg M., et al. iFR Swedeheart Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-1823.

4. Patel M. “Cost-effectiveness of Instantaneous Wave-free Ratio (iFR) compared with Fractional Flow Reserve (FFR) to guide coronary revascularization decision making.” Late-breaking Clinical Trial presentation at ACC on March 10, 2018.